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Abstract
Background: Fibrocytes are a population of circulating bone-marrow-derived cells that express surface markers for
leukocytes and mesenchymal cells, and are capable of differentiating into myofibroblasts. They have been observed
at sites of active fibrosis and increased circulating numbers correlate with mortality in idiopathic pulmonary fibrosis
(IPF). Inhibition of chemokine (C-C motif) receptor 2 (CCR2) during experimental models of lung fibrosis reduces
lung collagen deposition, as well as reducing lung fibrocyte accumulation. The aim of the present study was to
determine whether human and mouse fibrocytes express functional CCR2.
Results: Following optimized and identical human and murine fibrocyte isolation, both cell sources were shown to
be positive for CCR2 by flow cytometry and this expression colocalized with collagen I and CD45. Human blood
fibrocytes stimulated with the CCR2 ligand chemokine (C-C motif) ligand 2 (CCL2), demonstrated increased
proliferation (P < 0.005) and differentiation into myofibroblasts (P < 0.001), as well as a chemotactic response (P <
0.05). Murine fibrocytes also responded to CCR2 stimulation, with CCL12 being more potent than CCL2.
Conclusions: This study directly compares the functional responses of human and murine fibrocytes to CCR2
ligands, and following comparable isolation techniques. We have shown comparable biological effects,
strengthening the translatability of the murine models to human disease with respect to targeting the CCR2 axis to
ameliorate disease in IPF patients.
Background
Fibrocytes are a population of circulating cells that have
been reported to express a variety of markers including
leukocyte markers (CD45, CD34), mesenchymal markers
(collagen I, fibronectin) and chemokine receptors (che-
mokine (C-C motif) receptor 3 (CCR3), CCR5, CCR7
and C-X-C chemokine receptor type 4 (CXCR4)) [1].
Human and mouse studies have demonstrated that
fibrocytes from peripheral blood migrate to skin wound
chambers [1-3] and bronchial mucosa after antigen chal-
lenge [4]. Furthermore, these cells have been reported in
disease states with fibrotic pathologies including hyper-
trophic scars, asthma and idiopathic pulmonary fibrosis
(IPF) [4-7]. Fibrocytes are functionally pleiotropic,
potentially contributing to fibrogenesis by directly pro-
ducing collagen, as well as inflammatory cytokines,
hematopoietic growth factors, and chemokines [6-10].
In preclinical models of lung fibrosis, inhibition of var-
ious chemokine receptor/ligand pathways reduces lung
fibrosis and it has been hypothesized to be in part due
to a reduction in fibrocyte recruitment [6-9]. However,
the effect of inhibiting specific chemokine receptors
expressed on fibrocytes in the clinical setting remains to
be elucidated. CCR2 is the high-affinity receptor for its
ligand chemokine (C-C motif) ligand 2 (CCL2) (mono-
cyte chemoattractant protein 1 (MCP-1)). We have
recently shown that IPF patients have increased CCL2
in the circulation [11]. However, the expression of
CCR2 on human fibrocytes has yet to be described. In
murine models of fibrosis, CD45
+ lung fibrocytes iso-
lated from the lung express CCR2 [6]. Inhibition of this
chemokine axis through monoclonal antibody
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fluorescein isothiocyanate (FITC)-induced fibrosis, with
a concomitant reduction in fibrocyte number in the
lung [7]. Further, in vitro, mCCL2/JE and mCCL12/
MCP5 promote lung-derived fibrocyte migration [6,7].
Several studies have recently demonstrated increased
fibrocytes in the circulation of patients with fibrotic
lung disease [12,13], and the presence and modulation
of fibrocytes in experimental models of lung fibrosis
[6,9,14]. However, one confounding issue when compar-
ing interpretations across different laboratories is that
the isolation techniques, fibrocyte cell markers and iso-
lation parameters vary. Therefore, we sought to directly
compare fibrocytes from human and mouse blood using
an optimized technique, and measured functional
responses in the same assay systems, thus enabling
cross-species comparisons.
Methods
Fibrocyte isolation from human and murine peripheral
blood
For collection of human blood, all necessary permissions,
approvals, and licenses, including approval by a relevant
third party Institutional Review Board (IRB) of an
Informed Consent Form and Protocol and any relevant
study-related documentation required by the IRB, were
collected and maintained for the sourcing, handling, sto-
rage, banking, transport, or use of biological samples from
employee volunteers at Centocor, R&D, Inc. For BALB/c
mouse blood collection, all animal studies were approved
by the Centocor Institutional Animal Care and Use Com-
mittee (IACUC) in accordance with Federal guidelines.
Total peripheral blood mononuclear cells (PBMCs) were
isolated from human (60-100 ml of blood was drawn from
healthy donors 20-60 years of age) or murine blood
(approximately 1 ml of blood was drawn from each mouse
(6-10 weeks of age) and the blood was pooled from 10
mice) by centrifugation over Ficoll-Paque (Pharmacia,
Uppsala, Sweden) following the manufacturer’sp r o t o c o l .
After 2 days in culture on uncoated culture dishes in Dul-
becco’s modified Eagle medium (DMEM; Life Technolo-
gies, Gaithersburg, MD, USA) supplemented with 20%
fetal calf serum (FCS; HyClone Labs, Logan, UT, USA),
the non-adherent cells were removed by a single, gentle
aspiration. Following 10 to 12 days of continuous culture
for human blood and 14-18 days for murine blood, the
adherent cells were lifted by incubation in Accutase (Milli-
pore, Billerica, MA, USA) and were depleted by immuno-
magnetic selection of contaminating T cells (pan-T, anti-
CD2; Miltenyi Biotech, Auburn, CA, USA), monocytes
(anti-CD14, Miltenyi Biotech), and B cells (Pan-B, anti-
CD19, Miltenyi Biotech). Cell viability was determined to
be >90% by Guava analysis (Millipore). Immunohisto-
chemistry (IHC) and flow cytometry staining of this
population confirmed that these cells were positive for
both CD45 and collagen-I fibrocyte markers. Typically, the
isolated blood fibrocytes from both human (n = 4) and
mouse blood (n = 3, 10 mice pooled per experiment)
represented less than 0.5% of the starting PBMC pool.
Immunohistochemistry
For immunofluorescence, cells were seeded into eight-
well chamber slides at 1.5 × 10
4 viable cells/well and
were fixed when semiconfluent (day 7) in 3% formalde-
hyde for 10 min at room temperature and subsequently
washed several times in phosphate-buffered saline (PBS).
The cells were permeablized with methanol for 10 min
at -20°C and washed in staining buffer (0.2% bovine
serum albumin (BSA) (Sigma Aldrich, St. Louis, MO,
USA) and 0.02% sodium azide in PBS). Blocking of non-
specific antibody binding was performed with Universal
power blocking solution (Biogenex, San Ramon, CA,
USA) for 5 min at room temperature and washed in
staining buffer. Blocked slides were incubated for 2 h at
room temperature in staining buffer with primary anti-
bodies. Human cells were stained with chicken anti-
human CCR2 polyclonal antibody (Genway Biotech Inc,
San Diego, CA, USA) and mouse anti-human CD45
monoclonal antibody (eBiosciences, San Diego, CA,
USA). Murine cells were stained with chicken anti-
human CCR2 polyclonal antibody (Genway Biotech), rat
anti-mouse CD45 monoclonal antibody (BD Biosciences,
San Jose, CA, USA) and rabbit anti-mouse collagen I
polyclonal antibody (Chemicon, Temecula, CA, USA).
Murine cells were costained with either CD45 and col-
lagen I, or CCR2 and CD45, or CCR2 and collagen I.
Isotype controls were used for non-specific background
which included: chicken IgY isotype control (Southern-
Biotech, Birmingham, AL, USA), mouse IgG1 isotype
control (BD Biosciences), rat IgG2b isotype control (BD
Biosciences) and rabbit IgG isotype control (Imgenex,
San Diego, CA, USA). The cells were washed three
times in staining buffer. The secondary antibody was
added and incubated for 1 h in the dark. The secondary
antibody for CCR2 was goat anti-chicken IgY-FITC
(Genway Biotech), CD45 was Alexa Fluor 594 goat anti-
rat IgG (H+L) (Molecular Probes, Eugene, OR, USA)
and collagen I was Alexa Fluor 647 goat anti-rabbit Ig
(H+L) (Molecular Probes). Stained slides were washed
three times and mounted (Slowfade Gold antifade with
4’,6-diamidino-2-phenylindole (DAPI); Molecular
Probes). All slides were viewed on the laser confocal
microscope (UltraVIEW ERS spinning disk; Perkin
Elmer, Wellesley, MA, USA).
Flow cytometry analysis
For flow cytometry analysis, 2 × 10
5 viable cells were
added to flow tubes and centrifuged. The cells were
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0.02% sodium azide in PBS) and 1 μlo fF cb l o c k e r( B D
Biosciences). The cells were incubated for 10 min. Spe-
cies-relevant phycoerythrin (PE)-conjugated anti- CD45
monoclonal antibodies (BD Biosciences) were added and
incubated for 40 min after which the cells were washed
three times with staining buffer, fixed and permeabilized
by adding BD cytofix/cytoperm (BD Biosciences) for 20
min. The cells were centrifuged and resuspended in
blocking solution (BD buffer solution) for 5 min. The
cells were incubated for 40 min with chicken anti-
human CCR2 primary antibody (Genway Biotech) and
biotin anti-collagen I (Rockland, Gilbertsville, PA, USA).
The cells were washed three times with BD buffer and
the secondary antibody for CCR2, FITC-IgY antibody
(Genway Biotech) and for collagen I, streptavidin-APC
(BD Biosciences) was added and incubated for 30 min.
The cells were washed three times and fixed with 3%
paraformaldhyde. Isotype controls used for non-specific
background included: chicken IgY isotype control
(SouthernBiotech), PErat IgG2b isotype control (BD
Biosciences), rat IgG2a isotype control (BD Biosciences),
and IgG fraction of anti-Biotin (Rockland).
Cell proliferation assay
Selected human and murine blood fibrocytes were pla-
ted at 0.5 × 10
4 viable cells/well in a 96 well tissue cul-
ture plate. The cells were incubated in control media
(10% BSA in DMEM) overnight. The media was
removed and replaced with mCCL2 (1 μM equivalent to
8.8 ng/ml) (Peprotech, Rocky Hill, NJ, USA), CCL12 (1
μM equivalent to 9.3 ng/ml) (Peprotech) or platelet-
derived growth factor (PDGF)-AB (Peprotech) for mur-
ine fibrocytes and hCCL2 (Peprotech) or PDGF-AB for
human fibrocytes in serum free media (1% BSA and
insulin transferrin selenium (ITS; Invitrogen, Carlsbad,
CA, USA) in DMEM). The fibrocyte cells were incu-
bated for 96 h at 37°C in a humidified chamber. The
proliferative activity was measured using CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison,
WI, USA). CellTiter-Glo is a homogeneous method of
determining the number of viable cells in culture
through generation of a luminescent signal based on
quantitation of the ATP present, an indicator of meta-
bolically active cells [15].
Cell surface ELISA for a-smooth muscle actin in fibrocytes
Selected human blood fibrocytes were plated at 1.5 ×
10
4 cells/well in an opaque 96 well tissue culture plate.
The cells were incubated in control media (10% BSA in
DMEM) overnight. The media was removed and replace
with hCCL2 or transforming growth factor (TGF) b
(Peprotech) in serum free media (1% BSA and ITS in
DMEM). The cells were incubated for 96 h at 37°C in a
humidified chamber. a-Smooth muscle actin (SMA)
expression was evaluated on 96 well plates (cell surface
ELISA) as previously reported [16-18]. Briefly, the cells
were fixed by adding 100 μl of cold 100% methanol.
The methanol was removed after 10 min and the wells
were washed three times with 100 μl of PBS plus 0.5%
Tween-20 (Wash buffer). The wells were then blocked
with 3% H2O2 for 3 min before being washed three
times with 100 μl of wash buffer. The cells were blocked
a second time using DMEM containing 2% FCS for 20
min before being washed three times with 100 μlo f
wash buffer. The primary antibody a-smooth muscle
actin (Sigma Aldrich) was added to the cells and incu-
bated for 60 min at room temperature. The cells were
washed with 100 μl of wash buffer and incubated with
secondary antibody (Anti-mouse conjugated with horse-
radish peroxidase; Sigma Aldrich) for 60 min at room
temperature. The secondary antibody was then removed
and the wells were washed three times. A total of 100 μl
of 2,2"-azino-bis[3-ethylbenzothiazoline-6-sulfonate]
(ABTS, Sigma Aldrich) was added into the wells and
incubated for 60 min at room temperature. The reaction
was stopped by adding 100 μl of 1% SDS into each well.
The optical density of the wells was analyzed using a
plate reader at wavelength of 405 nm.
Chemotactic migration assay
The blood fibrocytes were assayed in a 300 μl, 96-well
microplate ChemoTx system using 5 μm PVP-free poly-
carbonate filters (Neuroprobe Inc., Gaithersburg, MD,
USA) [19]. Chemotactic stimuli was CCL2 (Peprotech)
diluted to different concentrations (n = 4-5 per sample
condition) in 2% BSA in DMEM and added in the bot-
tom wells of the chamber. 2% BSA in DMEM alone was
added in the bottom of the chamber as a negative con-
trol (random chemotaxis). Cells were suspended in 60 μl
of 2% BSA in DMEM (30 000 cells/well) and added on
the top of the chamber Cells were allowed to migrate
o v e r n i g h ta t3 7 ° Ci na5 %C O 2 incubator. After migra-
tion, cells were wiped from the top filter and the plate
was centrifuged at 500 g. The cells were resuspended in
100 μl and cells migrating across the membrane into the
lower chamber were determined using the Cell Titer-
Glo Luminescence Cell Viability Assay. The chemotaxis
index of hCCL2 was calculated by comparing the num-
ber of cells that migrated towards hCCL2 in comparison
to the number of cells that spontaneously migrated into
the bottom chamber.
Statistical analysis
Differences between multiple groups were analyzed by
analysis of variance (ANOVA) using least significant dif-
ference method. A P value < 0.05 was considered
significant.
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We assessed the phenotype and in vitro function of
fibrocytes, or bone-marrow-derived collagen-producing
cells, isolated from human and murine blood. Therefore
in order to be able to directly compare the phenotype
and function of human with mouse fibrocytes, we used
identical isolation techniques.
Blood fibrocytes express CCR2
A key morphological characteristic of fibrocytes is the
irregular star or spindle shape [2,9,20]. Under our cul-
ture conditions, we observed cells from human and
murine blood exhibiting this morphology (Figures 1 and
2). In the human cell system, using confocal microscopy,
we detected CCR2 expression being coexpressed in the
elongated CD45
+ cells (Figure 1). In the mouse blood
derived cells, the majority of cells were CD45
+ collagen
I
+ (Figure 2). Here CCR2 expression was colocalized
with both CD45
+ and collagen I
+ (Figure 2).
To quantify the expression of CCR2 on human and
murine cultured fibrocytes, freshly isolated peripheral
blood mononuclear cells were triple stained with CD45,
collagen I and CCR2 and enumerated by flow cytometry.
Approximately 97% of the human blood fibrocytes were
CD45 and collagen I positive (Figure 3C). Of this popu-
lation, the cells were strongly positive for CCR2 (Mean
fluorescence intensity (MFI) = 1221) compared to the
IgY isotype control (MFI = 41) (Figure 3D). In mice,
approximately 92% of the cultured blood cells stained
strongly for collagen I and 32% of this population also
expressed CD45 (Figure 3G). A time-dependent loss of
CD45 in human fibrocyte culture has been observed
previously [9]. Therefore, reduced CD45 expression in
the murine versus human fibrocytes in this study may
have been due to the extended time required for mouse
fibrocyte culture. We observed that murine blood fibro-
cytes (MFI = 230) and the CD45
- collagen I
+ (MFI =
186) were strongly positive for CCR2 compared to the
IgY isotype control (MFI = 63) (Figure 3H). When com-
paring multiple human donors and mouse blood sam-
ples, approximately 10% of human fibrocytes and 4% of
mouse fibrocytes are CCR2 positive (Figure 3I).
CCL2 increases blood fibrocyte proliferation
Fibroblast proliferation is a key hallmark of IPF [21]. We
next examined whether fibrocyte proliferative capacity
could be increased by stimulation with CCR2 ligands.
Here, we were able to further demonstrate that blood
fibrocytes have functional CCR2, as exogenous CCR2
ligands significantly enhanced proliferation in vitro (Figure
4). In the human blood fibrocytes, 10 ng/ml of hCCL2
induced a significant increase in fibrocyte proliferation,
with 50 ng/ml of hCCL2 inducing the greatest effect (P <
0.005), with a 45% increase on cell proliferation (Figure
4A). In the CCR2 ligand assessments, murine fibrocytes
were responsive to mCCL12 with both 50 and 100 ng/ml
inducing proliferation (Figure 4B). However, mCCL2 did
not mediate a significant induction of fibrocyte prolifera-
tion at any of the concentrations tested (Figure 4B). In
both the human and murine fibrocytes, PDGF, a fibroblast
mitogen [22] also produced a modest increase in fibrocyte
proliferation by approximately 20% (P >0 . 1 )( F i g u r e4 ) ,
but was not as potent as exogenous CCR2 ligands.
CCL2 enhanced blood fibrocyte differentiation into
myofibroblast phenotype
The fibrotic lesions observed in the lungs of IPF patients
contain a-SMA
+ myofibroblasts [21]. Fibrocytes are
hypothesized to migrate to the lung and differentiate
into cell types reminiscent of fibroblasts or a-SMA
+
myofibroblasts. To determine if CCR2 has a role in this
hallmark feature of fibrosis, we studied whether human
fibrocytes could differentiate into myofibroblast-like
cells in response to TGFb or hCCL2. TGFb is an impor-
tant fibrogenic and growth-regulating cytokine involved
in tissue remodeling and is a potent inducer of fibro-
blast to myofibroblast differentiation, as well as mono-
cyte to fibrocyte differentiation [1,3,4,23,24]. In our
study, culturing human blood derived fibrocytes in
serum-free media results in the expression of a-SMA at
the protein level (Figure 5). However, administration of
exogenous TGFb increased a-SMA expression by 24%
in human blood fibrocytes. hCCL2 also increased a-
SMA protein expression, with 100 ng/ml of hCCL2
mediating the greatest induction of a-SMA (54%, P <
0.001, Figure 5).
Figure 1 Positive chemokine (C-C motif) receptor 2 (CCR2)
expression in human blood fibrocytes by confocal microscopy.
Fibrocytes after primary passage were costained with CCR2 and
CD45 or isotype controls (chicken IgY and murine IgG1). Nuclei were
stained with 4’,6-diamidino-2-phenylindole (DAPI; blue). Cells were
examined at 60 × magnification. Representative images from three
donors.
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As fibrocytes are circulating bone-marrow-derived cells,
we next assessed the ability of these cells to undergo
chemotactic migration in response to hCCL2. Human
isolated fibrocytes were added to the bottom chamber of
a chemotaxis plate and increasing concentrations of
hCCL2 were added to the top chamber. Only 100 ng/ml
of hCCL2 was able to induce a significant migratory
Figure 2 Positive chemokine (C-C motif) receptor 2 (CCR2) expression in murine blood fibrocytes by confocal microscopy. Fibrocyte
cultures were costained with CD45 and collagen I (A), CCR2 and CD45 (B), or CCR2 and collagen I (C). Fibrocytes were stained with isotype
controls chicken IgY, rabbit IgG, and rat IgG2b(D). Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI; blue). Cells were examined at 40
× magnification. Representative images from blood pooled from n = 30 mice.
Ekert et al. Fibrogenesis & Tissue Repair 2011, 4:23
http://www.fibrogenesis.com/content/4/1/23
Page 5 of 9response in these cells (P < 0.05) (Figure 6). There was a
non-significant trend with the lower concentrations of
hCCL2.
Discussion
Circulating fibrocytes have been described to be one of
the potential sources of increased extracellular matrix
and myofibroblasts that are hallmarks of fibrotic
pathologies [8,25]. Fibrocytes derived from the bone mar-
row migrate to sites of tissue injury and may enhance
fibrosis directly through the production of collagen and
profibrotic factors [14,25,26]. Inhibition of fibrocyte
recruitment and/or activation could thus allow distinct
therapeutic paths to treat a range of fibrotic diseases. We
have shown that both human and murine fibrocytes
express CCR2 and stimulation of this receptor with
Figure 3 Positive chemokine (C-C motif) receptor 2 (CCR2) expression in human and murine blood fibrocytes by flow cytometry.
Representative flow cytometric analysis of fibrocytes stained after primary passage with collagen I, CD45 and CCR2 or isotype controls. (C)
Collagen I and CD45 staining of human fibrocytes with gate parameters calculated based in isotype controls (A and B). (D) Representative
histogram of CCR2 expression (blue) in human fibrocyte population compared to IgY isotype control (red). (G) Collagen I and CD45 staining of
murine fibrocytes with gate parameters calculated based in isotype controls (E and F). (H) Representative histogram of CCR2 expression (blue)
and collagen I (green) compared to relevant isotype control (red). (I) Quantitative analysis of percentage of CCR2+ cells in fibrocyte population.
Data are expressed as the mean ± SEM of n = 4 human donors and n = 30 mice.
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responses including differentiation and proliferation. In
experimental models of lung fibrosis, blockade of CCR2
ligands results in a reduction in collagen deposition [6,7].
Therefore this study directly confirms CCR2 expression
and function between mouse cells and human cells
which may directly translate into human disease.
Human peripheral blood fibrocytes have been shown
to express a variety of chemokine receptors including
CCR7 and CXCR4 [8,25]. Murine models have impli-
cated a role for fibrocytes in contributing to the patho-
g e n i cr e m o d e l i n gd u r i n gp u l monary fibrosis [7,14,25].
However, translating function and effect on chemokine
neutralization, to human clinical disease has yet to be
demonstrated. In this study, we showed that CCR2 is
expressed on human and murine blood fibrocytes. A Figure 4 Chemokine (C-C motif) receptor 2 (CCR2) ligand
promotes proliferation of human and murine blood fibrocytes.
Human blood fibrocytes (A) were stimulated with human
chemokine (C-C motif) ligand 2 (hCCL2) or platelet-derived growth
factor (PDGF)-AB and murine blood fibrocytes (pooled blood from n
= 10 mice) (B) were stimulated with mCCL2, mCCL12 or PDGF-AB.
Cells were grown for 4 days before proliferative activity was
measured using CellTiter-Glo Luminescent Cell viability. *P < 0.05,
significantly different compared with untreated fibrocytes. ***P <
0.005, significantly different compared with untreated fibrocytes.
Data are expressed as the mean ± SEM (n = 3 replicates per
treatment group) (representative of three separate experiments).
Figure 5 Chemokine (C-C motif) receptor 2 (CCR2) ligand
induces differentiation of human blood fibrocytes. Human
blood fibrocytes were stimulated with human chemokine (C-C
motif) ligand 2 (hCCL2) or transforming growth factor (TGF)b and
grown for 4 days before a-smooth muscle actin levels were
analyzed. The optical density (OD) reading is the level of a-smooth
muscle actin, which relates to the amount of fibrocyte
differentiation into myofibroblasts. *P < 0.05, significantly different
compared with untreated fibrocytes. ***P < 0.005, significantly
different compared with untreated fibrocytes. Data are expressed as
the mean ± SEM (n = 3 replicates per treatment group)
(representative from three separate experiments).
Figure 6 Chemokine (C-C motif) ligand 2 (CCL2) induced
chemotactic response in human blood fibrocytes. Human blood
fibrocytes were subjected to chemotaxis in response to the
indicated hCCL2 concentrations overnight. *P < 0.05, significantly
different compared with untreated fibrocytes. Data are expressed as
the mean ± SEM (n = 3 healthy humans performed in
quadruplicate per treatment group).
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lung tissues revealed the murine CCR2 receptor to be
highly expressed and to mediate migration ex vivo [6].
Human and murine peripheral blood fibrocytes have
also been shown to express CCR2 [27,28]. We have
extended these studies by assessing other chemokine-
associated functions. Moreover, importantly we have
shown a commonality between the murine and human
system, in that both human and murine cultured fibro-
cytes express functional CCR2. A natural extension of
these studies would be to assess and compare CCR2 on
fibrocytes isolated from patients with IPF with those iso-
lated during murine models of lung fibrosis.
To investigate the functional responses to CCR2 acti-
vation, we analyzed the effects of CCR2 ligands on var-
ious activation responses in cultured blood-derived
fibrocytes. We focused on processes associated with
fibrosis such as differentiation to myofibroblasts, prolif-
eration and migration. Fibrocytes are extremely adherent
cells when isolated and cultured in vitro. However,
CCL2 promoted the chemotactic migration of fibrocytes.
Studies have demonstrated increased CCL2 in the circu-
lation [29] and in the lungs [30,31] of IPF patients and
there is evidence for a possible concentration gradient
that may enable chemoattraction activity of CCL2 [31].
Therefore, this chemokine axis may be central to the
observed increase in the number of fibrocytes seen in
the blood [13] and lungs [32] of IPF patients.
Previous reports have linked IL-1b and tumor necrosis
factor a, to enhancing fibrogenic responses in vivo,a n d
demonstrated an increase in the secretion of chemokines
(CCL2 and CXCL8) and hematopoietic growth factors (IL-
6 and M-CSF) in human peripheral blood fibrocytes [3].
We observed no significant CCL2-induced secretion of
cytokines by human and murine peripheral blood fibro-
cytes (data not shown). Key hallmarks of active fibrotic
lesions are the presence of myofibroblasts and a prolifera-
tion of collagen producing cells [33-35]. TGFb and
endothelin-1 (ET-1) can promote fibrocyte differentiation
into myofibroblasts resulting in a cell population produ-
cing increased collagen and having contractile properties
[1,4]. We evaluated whether human blood fibrocytes could
differentiate into myofibroblast-like cells under the influ-
ence of CCL2. Here, we show that CCL2 promotes myofi-
broblast differentiation, as detected by increased a-SMA
expression. Recent studies in human blood fibrocytes have
shown that a variety of mediators including TGFb and
cysteinyl leukotrienes modulate fibrocyte proliferation and
interestingly TGFb induced effects on IPF fibroblasts that
are partly mediated via CCL2 [4,36].
Here, we demonstrate that exogenous hCCL2 and
mCCL12 lead to increased blood fibrocyte proliferation
in human and murine cells respectively. Interestingly,
mCCL2 did not induce mouse fibrocyte proliferation.
Both mouse chemokines have been shown to bind to
and signal through CCR2 with similar potencies [22].
However, it is has been proposed that mCCL12 may uti-
lize another receptor in addition to CCR2 [22]. In the
human blood fibrocyte studies, human cells responded
to low levels of hCCL2 stimulation. There is no human
homologue of mCCL12; therefore this data suggests that
human CCL2 may be more like murine CCL12 with
respect to fibrocyte function.
Conclusions
In summary, the current study, using an optimized fibro-
cyte isolation technique from both mouse and human
blood, has demonstrated the presence of functional CCR2
on a subpopulation of human and murine blood fibrocyte
cells. Signaling through ligand-CCR2 interactions in both
human and murine blood fibrocytes induced fibrocyte
proliferation, differentiation of fibrocytes into myofibro-
blasts, and a chemotactic response. Comparable CCR2
expression and biological activity of CCR2-CCL2/CCL12
in both murine and human fibrocytes was detected. Precli-
nical murine models of lung fibrosis have demonstrated
potent therapeutic activity mediated by inhibiting this che-
mokine axis [6,7,10]. Additionally, fibroblasts from the
lungs of IPF patients are hyper-responsive to CCL2,
whereas fibroblasts isolated from non-fibrotic lesions do
not respond to CCL2 [10]. Taken together, this highlights
the potential for an anti-CCR2/CCL2 approach at inhibit-
ing human lung fibrosis through attenuating fibroblast
activity directly as well as reducing downstream fibrocyte
profibrotic activities.
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